Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

1.740 +0.050 (+2.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
NMRA Investor Alert: Contact Kessler Topaz Meltzer &amp; Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
RADNOR, PA - February 15, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
NMRA Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
Kessler Topaz Meltzer & Check, LLP Class Action Announcement NMRA: A Securities Fraud Class Action Lawsuit Was Filed Against Neumora Therapeutics, Inc. (NMRA)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
Class Action Announcement for Neumora Therapeutics, Inc. (NMRA): Kessler Topaz Meltzer & Check, LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Class Action Announcement for Neumora Therapeutics, Inc. (NMRA): Kessler Topaz Meltzer &amp; Check, LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc.
RADNOR, PA - February 13, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Neumora Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NMRA
From Robbins LLP
Via GlobeNewswire
Neumora Therapeutics Announces Leadership Transition
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That Neumora Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA
From The Rosen Law Firm, P.A.
Via Business Wire
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
From DJS Law Group
Via Business Wire
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in May
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
From Neumora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.